Skip to content

Depression: all studies

Page 789 of 1,036: studies 7,881 to 7,890 of 10,358, newest first. Back to the depression overview

Research

Acute Ketamine Modulated Functional Brain Coupling and Dissociative and Affective States in Human Subjects: Interim Analyses

bioRxiv Preprint Server September 20, 2021 Laura M Hack, Katherine G. Warthen, Xue Zhang et al. 2 citations preprint

Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor that is both a drug of abuse and an FDA-approved anesthetic used off-label for treatment-resistant depression. Despite its growing clinical use for depression and pain, the relationships between the acute dissociative and affective effects of ketamine that contribute to its abuse liability and...

Increasing Prevalence of Ketamine in Drivers in New York City Including the Identification of 2-Fluoro-Deschloroketamine.

Journal of Analytical Toxicology September 17, 2021 Elba Arango, Allison Toriello, Zoila Rosario et al. 17 citations

Ketamine is a dissociative anesthetic used in veterinary and human medicine since the 1970s. Its clinical use has expanded to control of seizures, by pre-hospital emergency medical services (EMS), and is finding new purpose as an analgesic alternative and antidepressant. Ketamine brings hope for effective management of chronic pain in the absence of opioids and decreasing suicidal ideations;...

New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances

European Psychologist September 17, 2021 Matthias Forstmann, Christina Sagioglou 6 citations

Abstract. After decades of stagnation, research on psychedelic substances (such as lysergic acid diethylamide [LSD], psilocybin, or N,N-dimethyltryptamine [DMT]) has experienced a renaissance over the last 10 years, with various major research programs being conducted across Europe and the United States. This research primarily investigates the potential of psychedelics in the treatment of...

Neuroprotective effects of curcumin-loaded nanophytosome on ketamine-induced schizophrenia-like behaviors and oxidative damage in male mice.

Neuroscience Letters September 15, 2021 A. Hajizadeh Moghaddam, Khadijeh Maboudi, Bita Bavaghar et al.

Curcumin as an antioxidant natural herb has shown numerous pharmacological effects. However, the poor bioavailability of curcumin is a significant pharmacological barrier for its antioxidant activities. The present study was conducted to develop curcumin-loaded nanophytosome (CNP) and explore their therapeutic potential in a ketamine (KET)-induced schizophrenia (SCZ) model. The mice in our...

The therapeutical role of psychedelic drugs in treatment of mental disorders

Bulletin of Integrative Psychiatry September 15, 2021 Dan Cătălin Oprea, Loretta Epure, Vasile Chiriță et al.

Psychedelic drugs (also called hallucinogens, psychotogenics, psycholytics, entheogens) are substances that act mainly on the 5-HT2 serotonergic receptor.There are two main groups of psychedelics: indoleamines (lysergic acid diethylamide-LSD, N, N-dimethyltryptamine-DMT, and psilocybin) and phenethylamines (mescaline, dimethoxymethamphetamine-DOM, methylenedioxyamphetamine-MDA, and...

Dreams and Trauma Changes in the Manifest Dreams in Psychoanalytic Treatments – A Psychoanalytic Outcome Measure

Frontiers in Psychology September 14, 2021 Tamara Fischmann, Gilles Ambresin, Marianne Leuzinger-Bohleber 9 citations

Although psychoanalysts are interested in symptom reduction as an outcome, they are looking for instruments to measure sustaining changes in the unconscious mental functioning. In this article it is discussed that conceptually well-founded transformation of manifest dreams analyzed with precise empirical methods could be considered as a promising indicator for such therapeutic changes. We are...

DOI: 10.3389/fpsyg.2021.678440 (opens in new tab) Dream Psychoanalytic theory Psychoanalysis Unconscious mind +3

Ketamine ameliorates depressive-like behaviors in mice through increasing glucose uptake regulated by the ERK/GLUT3 signaling pathway

Scientific Reports September 13, 2021 Xin-ping Ouyang, Zhengjia Wang, Mei Luo et al.

To investigate the effects of ketamine on glucose uptake and glucose transporter (GLUT) expression in depressive-like mice. After HA1800 cells were treated with ketamine, 2-[N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino]-2-Deoxyglucose (2-NBDG) was added to the cells to test the effects of ketamine on glucose uptake, production of lactate, and expression levels of GLUT, ERK1/2, AKT, and AMPK....

Safety pharmacology of acute LSD administration in healthy subjects

Psychopharmacology September 13, 2021 Friederike Holze, Toya V Caluori, Patrick Vizeli et al. 57 citations

Abstract Rationale Lysergic acid diethylamide (LSD) is used in psychiatric and psychological research and investigated as a potential treatment for medical and psychiatric disorders, including depression, anxiety, and cluster headache. Objectives Safety data on clinical safety are available from small studies but not from larger samples. We report safety pharmacology data from a large pooled...

Effects of Mindfulness-Based Internet Intervention on ICD-11 Posttraumatic Stress Disorder and Complex Posttraumatic Stress Disorder Symptoms: a Pilot Randomized Controlled Trial.

Mindfulness September 11, 2021 Austeja Dumarkaite, Inga Truskauskaite-Kuneviciene, Gerhard Andersson et al.

Objectives: A substantial proportion of trauma survivors with posttraumatic stress disorder (PTSD) and complex PTSD (CPTSD) continue to experience symptoms even after trauma-focused therapies. Internet-based interventions could facilitate access to treatment for PTSD and CPTSD. The current pilot study aimed to investigate the effects of mindfulness-based internet intervention on PTSD and CPTSD...

New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy

Frontiers in Psychiatry September 10, 2021 Tehseen Noorani, Jonny Martell 32 citations

The publication in April 2021 of the Imperial College London Phase II study investigating \nthe efficacy of psilocybin-assisted therapy vs. escitalopram for depression reported differences \nin the primary outcome measure (the QIDS-SR16) between experimental and control arms as \nstatistically insignificant (1). However, secondary measures of depression, and other relevant \nmeasures (see...

DOI: 10.3389/fpsyt.2021.727050 (opens in new tab) Bursting Psychotherapist Psychoanalysis